Zobrazeno 1 - 10
of 38
pro vyhledávání: '"M. N. Chikina"'
Publikováno v:
Ожирение и метаболизм, Vol 19, Iss 4, Pp 378-386 (2023)
BACKGROUND: Patients with gout often take glucocorticoids (GCs) and are at high risk of developing type 2 diabetes mellitus (DM2).AIM: Evaluation of the effect of long-term use of low doses of GCs on the risk of developing DM in patients with gout ba
Externí odkaz:
https://doaj.org/article/c5c92d67d5b64d58b14ec6ad45e9d868
Publikováno v:
Современная ревматология, Vol 16, Iss 1, Pp 52-59 (2022)
The development of type 2 diabetes mellitus (DM) (DM2) in patients with gout can be influenced by both conventional and directly linked to gout risk factors (RFs).Objective: to identify RFs for the development of DM2 in patients with gout, including
Externí odkaz:
https://doaj.org/article/e7ad80ea7c884d1f85f7567c86fce7fc
Publikováno v:
Сахарный диабет, Vol 24, Iss 6, Pp 521-528 (2022)
BACKGROUND: Gout is associated with a high incidence of type 2 diabetes mellitus (T2DM).AIM: To calculate the risk of T2DM on the FINDRISС scale, to assess the sensitivity and specificity of the scale in patients with gout based on the results of pr
Externí odkaz:
https://doaj.org/article/0d1e4e643ff04cfba4def1bfbf5dfeee
Autor:
M. S. Eliseev, M. N. Chikina, I. A. Guseva, O. V. Zhelyabina, E. Yu. Samarkina, N. V. Konovalova, D. A. Varlamov
Publikováno v:
Современная ревматология, Vol 15, Iss 6, Pp 55-60 (2021)
Achieving the target serum uric acid (UA) level is a priority in the treatment of gout.Objective: to study the relationship of the ABCG2 gene polymorphism (rs2231142) with the efficacy of allopurinol and febuxostat in patients with gout.Patients and
Externí odkaz:
https://doaj.org/article/4523d6a81a9e42a1950b73b8cdcfc385
Autor:
M. S. Eliseev, E. V. Cheremushkina, O. V. Zhelyabina, M. N. Chikina, A. A. Kapitonova, A. A. Novikova, E. I. Markelova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 6, Pp 76-83 (2021)
Anti-inflammatory therapy, such as colchicine (COL), has been suggested to affect the incidence of cardiovascular events in patients with calcium pyrophosphate crystal deposition disease (CPPD).Objective: to study the effect of anti-inflammatory ther
Externí odkaz:
https://doaj.org/article/75865715cca74821aab5e5f96695cf4d
Autor:
M. S. Eliseev, O. V. Zhelyabina, M. N. Chikina, E. I. Markelova, I. G. Kirillova, Yu. O. Korsakova, A. A. Kobriseva
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 6, Pp 708-714 (2021)
Endothelial dysfunction associated with chronic microcrystalline inflammation plays a role in the progression of atherosclerosis in calcium pyrophosphate crystal deposition diseases (CPPD).The aim of the study was to assess the dynamics of the develo
Externí odkaz:
https://doaj.org/article/6a8bc7a5d4394792a5c4e3d81102efa5
Autor:
M. S. Eliseev, O. V. Zhelyabina, A. M. Novikova, M. N. Chikina, E. I. Markelova, I. G. Kirillova, Yu. O. Korsakova, A. A. Kobriseva
Publikováno v:
Современная ревматология, Vol 15, Iss 5, Pp 33-38 (2021)
To this date there have been no studies of subclinical atherosclerosis in the patients with calcium pyrophosphate crystal deposition disease (CPPD); in osteoarthritis (OA) such works are rare.Objective: to assess the prevalence of subclinical atheros
Externí odkaz:
https://doaj.org/article/6c17c2ec6c6d4c598705fcbf77df57c4
Publikováno v:
Современная ревматология, Vol 15, Iss 4, Pp 50-55 (2021)
Objective: to investigate the efficacy and safety of low-dose colchicine in patients with gout receiving urate-lowering therapy (ULT).Patients and methods. A single-center prospective study included 113 patients with gout. The main group consisted of
Externí odkaz:
https://doaj.org/article/1cae0ff2406141f19d0398e84f7381b1
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 148-153 (2021)
Colchicine is a drug that has been known for several millennia, since the days of Ancient Egypt, but has been successfully used to treat gout to this day. The action of colchicine is based on microtubule damage, mitosis suppression, as well as the ab
Externí odkaz:
https://doaj.org/article/d77d0c62236b4d8f90a0922af21569b1
Autor:
M. S. Eliseev, O. V. Zhelyabina, A. M. Novikova, M. N. Chikina, M. K. Kurbanmagomedov, M. M. Urumova, E. V. Nikolaeva, S. O. Salugina, E. S. Fedorov, E. L. Nasonov, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 3, Pp 81-85 (2021)
The article presents a case of periodic fever (PF) in a 35-year-old patient, who did not have hereditary and proven genetic factors of the disease, which was characterized by an atypical course with variable in duration and frequency severe abdominal
Externí odkaz:
https://doaj.org/article/641c2818d76e414281cf9f5a14bd85a8